Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | THPO | P40225 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.30 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP14 | P50281 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21186416 | 0.92 | EPHX1 (0.38) | KDM4ESMN1; SMN2ALDH1A1MMP1MMP2 | |
| SCHEMBL8915468 | 0.81 | AAK1 (0.30) | — | |
| SCHEMBL18596276 | 0.81 | AAK1 (0.30) | — | |
| SCHEMBL8918588 | 0.81 | AAK1 (0.30) | — | |
| SCHEMBL14942952 | 0.79 | MMP1 (0.31) | MMP1MMP2MMP3MMP9MMP14 | |
| SCHEMBL12965975 | 0.79 | PREP (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL21186346 | 0.79 | PREP (0.32) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL16705489 | 0.78 | ALOX15 (0.36) | MAPTALOX15SMN1; SMN2MMP1MMP2 | |
| SCHEMBL19083735 | 0.77 | SMN1; SMN2 (0.39) | KDM4EMAPTTHRBALOX15NFKB1 | |
| SCHEMBL31730569 | 0.77 | SMN1; SMN2 (0.39) | KDM4EMAPTTHRBALOX15NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | THE GENERAL HOSPITAL CORPORATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | THE GENERAL HOSPITAL CORPORATION | 2019-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11559590-B2 | Granzyme B directed imaging and therapy | GZMB, CTSB, PRF1 | KDM4E 4633/4885MAPT 4496/4885THRB 1844/4885 |
| US-20190224348-A1 | Granzyme B Directed Imaging and Therapy | GZMB, CTSB, PRF1 | KDM4E 4633/4885MAPT 4496/4885THRB 1844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.